Erythropoietin Receptor Signaling in HIV: Implications for Therapy

Article · March 2024

CITATIONS
0

READS
9

2 authors:

Emmanuel Ifeanyi Obeagu
Kampala International University (KIU)
1,422 PUBLICATIONS **11,224** CITATIONS
SEE PROFILE

Getrude Uzoma Obeagu
Kampala International University (KIU)
384 PUBLICATIONS **3,307** CITATIONS
SEE PROFILE

Elite Journal of Haematology. Volume 2 issue 2(2024), Pp. 46-62

https://epjournals.com/journals/EJH

Erythropoietin Receptor Signaling in HIV: Implications for Therapy

*Emmanuel Ifeanyi Obeagu[1] and Getrude Uzoma Obeagu[3]

[1]Department of Medical Laboratory Science, Kampala International University, Ishaka, Uganda.
[2]Department of Medical Laboratory Science, School of Basic Medical and Health Sciences, Igbinedion University, Okada, Edo State, Nigeria.
School of Nursing Science, Kampala International University, Ishaka, Uganda.

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda.

E-mail: emmanuelobeagu@yahoo.com, obeagu.emmanuel@kiu.ac.ug, 0000-0002-4538-0161

Abstract

Human Immunodeficiency Virus (HIV) remains a global health challenge, necessitating continuous exploration of novel therapeutic avenues. Erythropoietin (EPO), traditionally recognized for its role in erythropoiesis, has emerged as a multifaceted cytokine with immunomodulatory properties. The activation of EPOR signaling in these cells has been linked to both anti-inflammatory and pro-survival effects, suggesting a potential dual role in the context of HIV infection. Moreover, evidence suggests that EPO may contribute to the maintenance of immune homeostasis by regulating cytokine production, immune cell differentiation, and apoptosis. The implications of EPO-EPOR signaling in HIV therapy are manifold. On one hand, the modulation of EPOR signaling presents an opportunity for developing adjunctive therapies to enhance immune function and mitigate HIV-induced immunosuppression. On the other hand, caution is warranted, as excessive EPO stimulation may lead to unintended consequences, such as viral replication and immune hyperactivation.

Keywords*: Erythropoietin, Erythropoietin Receptor, HIV, Signaling Pathways, Therapy, Immunodeficiency, Hematopoiesis, Inflammation*

Introduction

The persistent global burden of Human Immunodeficiency Virus (HIV) infection necessitates ongoing exploration of innovative therapeutic approaches to improve patient outcomes. While antiretroviral therapy (ART) has significantly extended the lifespan of individuals living with HIV,

Citation: Obeagu EI, Obeagu GU. Erythropoietin Receptor Signaling in HIV: Implications for Therapy. *Elite Journal of Haematology, 2024; 2(2):* 46-62

challenges such as drug resistance and long-term complications persist. In recent years, the role of erythropoietin (EPO), a cytokine traditionally associated with erythropoiesis, has garnered attention due to its diverse immunomodulatory functions. Understanding the intricate signaling pathways of the Erythropoietin Receptor (EPOR) in the context of HIV may unveil novel therapeutic targets, providing a complementary strategy to current treatment regimens. Emerging evidence has revealed the presence of EPOR on various immune cells, including CD4+ T cells, macrophages, and dendritic cells. This unexpected finding suggests a broader role for EPO beyond its classical hematopoietic function, implicating it in the regulation of immune responses. Elucidating the dynamics of EPOR expression and activation on immune cells during HIV infection is crucial for understanding the potential impact of EPO-EPOR signaling on the course of the disease.[1-20]

The multifaceted nature of EPO extends beyond its primary role in erythropoiesis, encompassing immunomodulation through diverse cellular processes. Activation of EPOR has been associated with anti-inflammatory effects, cell survival promotion, and modulation of cytokine production. These immunomodulatory properties raise intriguing possibilities for leveraging EPO-EPOR signaling to enhance immune function and counteract the immunosuppressive effects induced by HIV. Despite its potential benefits, the relationship between EPO and HIV is complex, presenting a dual-edged sword. While EPO-mediated immunomodulation may bolster host defenses, there is a concern that excessive stimulation of EPOR could inadvertently exacerbate viral replication and immune hyperactivation. Striking the right balance is essential for harnessing the therapeutic potential of EPO in the context of HIV without compromising patient safety. The dynamic landscape of HIV pathogenesis calls for continual innovation in therapeutic strategies. Current challenges, including drug resistance and long-term side effects, underscore the urgency of exploring alternative approaches. Investigating the role of EPO-EPOR signaling in HIV not only adds a layer of complexity to our understanding of the virus but also presents a unique opportunity for therapeutic innovation that complements existing antiretroviral strategies.[21-37]

This review aims to comprehensively examine the existing literature on EPO-EPOR signaling in the context of HIV infection, synthesizing current knowledge on the expression and activation of EPOR on immune cells, the immunomodulatory effects of EPO, and the potential implications for HIV therapy. By addressing these aspects, we seek to contribute to a nuanced understanding of the interplay between EPO and HIV, identifying gaps in knowledge and highlighting avenues for future research. The exploration of EPO-EPOR signaling in the context of HIV is not only academically intriguing but also holds significant clinical implications. Insights gained from this review may pave the way for the development of targeted therapeutic interventions, providing clinicians with additional tools to optimize HIV treatment strategies. Ultimately, a comprehensive understanding of EPO-EPOR signaling in HIV pathogenesis has the potential to reshape the landscape of HIV therapeutics, offering new avenues for improved patient care and outcomes.

Erythropoietin and its Receptor

Erythropoietin (EPO) and its receptor (EPOR) form a pivotal signaling axis critical for the regulation of erythropoiesis and maintenance of tissue oxygenation. EPO, a glycoprotein hormone primarily produced by the kidneys in response to hypoxic conditions, plays a central role in stimulating the proliferation, differentiation, and maturation of erythroid progenitor cells in the bone marrow. This process ensures the steady production of red blood cells, allowing the body to adapt to varying oxygen demands. The EPO receptor, EPOR, is expressed on the surface of erythroid progenitor cells, facilitating the specific binding of EPO and triggering intracellular signaling cascades upon activation. EPOR belongs to the cytokine receptor superfamily and is characterized by its ability to transduce signals through the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway. Binding of EPO to EPOR induces conformational changes in the receptor, leading to the activation of JAK2, which subsequently phosphorylates and activates STAT proteins. Activated STAT proteins translocate to the nucleus, where they regulate the expression of genes involved in erythropoiesis.[38-40]

Beyond its classical role in erythropoiesis, EPO-EPOR signaling has been identified in various non-erythroid tissues, including the brain, heart, and immune system. In the central nervous system, EPO has been recognized for its neuroprotective effects and ability to modulate neuronal function. Additionally, EPOR expression on immune cells, such as T cells and macrophages, suggests a broader role for EPO in immunomodulation. The therapeutic potential of EPO extends beyond its use in treating anemia associated with chronic kidney disease. Recombinant EPO has been employed in various clinical settings, including cancer-related anemia and neurodegenerative disorders. However, caution is warranted, as excessive EPO administration has been associated with adverse effects, including thrombosis and increased cardiovascular risks.[41-43]

The Crosstalk between EPO Signaling and HIV

The intricate crosstalk between erythropoietin (EPO) signaling and Human Immunodeficiency Virus (HIV) represents a dynamic interplay with significant implications for both viral pathogenesis and host immune responses. EPO, primarily recognized for its role in erythropoiesis, has emerged as a multifunctional cytokine capable of influencing various cellular processes, including those involved in the immune system. In the context of HIV, emerging evidence indicates the presence of EPO receptors (EPORs) on immune cells, including CD4+ T cells and macrophages. This unexpected discovery suggests that EPO may exert direct effects on cells susceptible to HIV infection, raising questions about the impact of EPO signaling on viral replication and immune responses. Furthermore, the activation of EPO signaling has been associated with anti-inflammatory effects and cell survival promotion, indicating a potential role in modulating the immune environment during HIV infection.[44-58]

One aspect of the crosstalk between EPO and HIV revolves around the intricate balance between immune enhancement and potential viral replication. While EPO-induced immunomodulation may contribute to the maintenance of immune homeostasis and the prevention of excessive

inflammation, there is a concern that increased EPOR stimulation might inadvertently provide a favorable environment for viral replication. Moreover, the impact of HIV on EPO signaling adds another layer of complexity. HIV infection itself may influence EPO levels, potentially disrupting the delicate balance required for erythropoiesis and immune regulation. The virus's ability to target and affect the bone marrow microenvironment may contribute to alterations in EPO production and responsiveness, influencing the overall health and hematological status of individuals living with HIV. As therapeutic strategies for HIV continue to evolve, the crosstalk between EPO signaling and HIV opens avenues for innovative approaches. Targeting EPO pathways may offer a unique opportunity to modulate immune responses and counteract HIV-induced immunosuppression. However, careful consideration of the potential risks, such as enhanced viral replication, is essential to ensure the safety and efficacy of any therapeutic interventions targeting the EPO-EPOR axis in the context of HIV.[59-75]

Immunomodulatory Effects of EPO in HIV

The immunomodulatory effects of erythropoietin (EPO) in the context of Human Immunodeficiency Virus (HIV) infection present a fascinating intersection of hematopoietic and immune regulatory pathways. Traditionally recognized for its pivotal role in erythropoiesis, EPO has been increasingly acknowledged for its broader impact on the immune system, and understanding these effects is crucial in the pursuit of novel therapeutic strategies for HIV. EPO has been associated with anti-inflammatory properties, suppressing the production of pro-inflammatory cytokines and modulating immune responses. In the context of HIV, characterized by chronic immune activation and inflammation, the anti-inflammatory effects of EPO could offer a potential avenue for dampening excessive immune responses and mitigating associated pathologies. EPO's ability to promote cell survival and inhibit apoptosis is of particular interest in the context of HIV, where the virus induces programmed cell death in immune cells. EPO's anti-apoptotic effects may contribute to the preservation of immune cell populations, potentially enhancing the host's ability to maintain functional immune responses despite ongoing viral replication.[76-91]

EPO has been shown to modulate the production of cytokines, influencing the balance between pro-inflammatory and anti-inflammatory signals. Given the dysregulated cytokine milieu in HIV infection, EPO's capacity to modulate cytokine profiles could contribute to a more controlled and balanced immune response, potentially impacting the progression of the disease.[92] As EPO demonstrates immunomodulatory effects, it raises the intriguing possibility of utilizing EPO as an adjunctive therapy to aid in immune reconstitution, particularly in individuals with HIV-associated immunosuppression. While the immunomodulatory potential of EPO is promising, caution is warranted, especially considering the dual role of EPO in HIV pathogenesis. Striking a balance between immune enhancement and the potential risk of increased viral replication is crucial for the safe and effective use of EPO as an immunomodulatory agent in the context of HIV.

EPO Receptor Signaling Pathways in HIV

The understanding of the immunomodulatory effects of erythropoietin (EPO) in the context of Human Immunodeficiency Virus (HIV) infection requires an exploration of the signaling pathways initiated by the EPO receptor (EPOR). While traditionally recognized for its role in erythropoiesis, EPO and its receptor have been identified on various immune cells, suggesting a broader impact on the immune system. In the specific context of HIV, the intricate signaling pathways activated by the EPO receptor may play a crucial role in shaping the host immune response and influencing the course of the viral infection. The primary signaling pathway activated by the binding of EPO to its receptor is the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway. Upon EPO binding, the EPO receptor undergoes conformational changes, leading to the activation of JAK2 (Janus kinase 2). Activated JAK2 phosphorylates tyrosine residues on the EPO receptor and subsequently recruits and activates STAT proteins (signal transducer and activator of transcription). These activated STAT proteins form dimers and translocate to the nucleus, where they regulate the transcription of target genes involved in various cellular processes, including cell survival, proliferation, and differentiation.[93-110]

EPO-induced activation of the JAK-STAT pathway has been associated with anti-apoptotic effects, particularly in the context of hematopoietic cells. In HIV, where CD4+ T cell depletion is a hallmark of the infection, the potential anti-apoptotic role of EPO signaling could be of particular relevance. EPO-mediated protection against apoptosis may contribute to the maintenance of CD4+ T cell populations and mitigate the detrimental effects of HIV-induced cell death. EPO signaling has been shown to modulate the production of various cytokines involved in immune responses. By influencing the balance of pro-inflammatory and anti-inflammatory cytokines, EPO may play a role in shaping the overall immune environment during HIV infection. This modulation could impact immune cell activation, differentiation, and the overall effectiveness of the host response against the virus. The expression of EPOR on non-erythroid tissues, including immune cells, implies that EPO signaling may have tissue-specific effects. In the context of HIV, where the virus can target multiple tissues and organs, understanding how EPO receptor signaling influences the immune response in different anatomical locations is essential. While EPO signaling may have beneficial effects on immune cells, promoting cell survival and modulating cytokine production, the potential dual role of EPO in HIV pathogenesis must be considered. Excessive EPO stimulation might inadvertently create an environment conducive to viral replication, necessitating a delicate balance in harnessing its immunomodulatory effects.[111-122]

Therapeutic Implications

The crosstalk between erythropoietin (EPO) signaling and Human Immunodeficiency Virus (HIV) has significant therapeutic implications, offering potential avenues for innovative interventions in the management of HIV infection.[123] Understanding the immunomodulatory effects of EPO in the context of HIV suggests that targeted modulation of EPO signaling could be explored as a

complementary strategy to enhance the host immune response. Fine-tuning EPO-mediated effects on immune cells may contribute to the maintenance of immune homeostasis, potentially mitigating HIV-induced immunosuppression. EPO-based interventions could be investigated as adjunctive therapies alongside existing antiretroviral treatments. By bolstering immune function and potentially mitigating CD4+ T cell depletion, EPO may enhance the overall effectiveness of HIV treatment regimens, particularly in individuals with compromised immune systems. HIV infection is known to impact the bone marrow microenvironment, affecting erythropoiesis and contributing to anemia. Leveraging EPO to support bone marrow function could be explored as a therapeutic approach to address HIV-associated anemia, improving overall hematological health in affected individuals.

Given EPO's neuroprotective properties, its therapeutic application may extend to addressing HIV-associated neurocognitive disorders.[124] Exploring the potential of EPO in preserving neuronal function and mitigating neuroinflammation could offer novel avenues for managing HIV-related neurological complications. Careful consideration of the timing and dosage of EPO administration is crucial to optimize therapeutic benefits while minimizing potential risks. Strategies that harness EPO's immunomodulatory effects without inadvertently promoting viral replication need to be developed and validated through rigorous clinical studies. Recognizing the potential dual role of EPO in HIV pathogenesis, patient stratification based on viral load, immune status, and other relevant factors becomes essential. Tailoring therapeutic approaches to individual patient profiles can maximize benefits while minimizing risks associated with EPO interventions. The implementation of monitoring and surveillance protocols is imperative to assess the safety and efficacy of EPO-based therapies in individuals living with HIV. Regular assessments of viral load, immune parameters, and hematological indices can guide the optimization of therapeutic strategies and help identify potential adverse effects. Integration of EPO-based therapies into comprehensive HIV care plans should be approached holistically. Collaborative efforts with existing antiretroviral therapies, supportive care measures, and management of comorbidities will be crucial for ensuring comprehensive and effective patient care.

Conclusion

The intricate interplay between erythropoietin (EPO) signaling and Human Immunodeficiency Virus (HIV) presents a multifaceted relationship with broad implications for both viral pathogenesis and therapeutic interventions. The identification of EPO receptors (EPORs) on immune cells and the activation of diverse signaling pathways in response to EPO binding highlight the intricate nature of this interaction. EPO's capacity to modulate immune cell function, promote cell survival, and influence cytokine production suggests a potential role in mitigating HIV-induced immunosuppression. However, the dual-edged nature of EPO, where excessive stimulation could inadvertently foster viral replication, necessitates a nuanced approach to therapeutic interventions.

Citation: Obeagu EI, Obeagu GU. Erythropoietin Receptor Signaling in HIV: Implications for Therapy. *Elite Journal of Haematology, 2024; 2(2):* 46-62

Therapeutically, harnessing EPO for its immunomodulatory properties holds promise as an adjunctive strategy to existing antiretroviral therapies. By strategically targeting EPO signaling, it may be possible to bolster immune function, support bone marrow health, and potentially address HIV-associated anemia and neurocognitive disorders. Nonetheless, careful patient stratification, monitoring, and integration with existing therapeutic modalities are essential to ensure the safety and efficacy of such interventions.

References

1. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. Madonna University journal of Medicine and Health Sciences. 2022;2(3):120-127.
2. Obeagu EI, Alum EU, Obeagu GU. Factors associated with prevalence of HIV among youths: A review of Africa perspective. Madonna University journal of Medicine and Health Sciences. 2023;3(1):13-18. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/93.
3. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023 ;3(1):7-12. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91.
4. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. J Pub Health Nutri. 2023; 6 (2). 2023; 141:1-2. links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf.
5. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
6. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. Int J Curr Res Med Sci. 2017;3(1): 21-38.DOI: 10.22192/ijcrms.2017.03.01.004
7. Obeagu EI, Obeagu GU, Musiimenta E, Bot YS, Hassan AO. Factors contributing to low utilization of HIV counseling and testing services. Int. J. Curr. Res. Med. Sci. 2023;9(2): 1-5.DOI: 10.22192/ijcrms.2023.09.02.001
8. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;129. links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf.
9. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.

Citation: Obeagu EI, Obeagu GU. Erythropoietin Receptor Signaling in HIV: Implications for Therapy. *Elite Journal of Haematology, 2024; 2(2):* 46-62

10. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
11. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. Journal of Pharmaceutical Research International. 2020;32(22):101-119.
12. Obeagu EI, Okoroiwu IL, Obeagu G. Molecular mechanism and systemic response of erythropoietin: A Review. Int. J. Adv. Res. Biol. Sci. 2015;2(7):58-62.
13. Obeagu EI, Okoroiwu II, Ezimah AC. Evaluation of serum erythropoietin levels in chronic kidney disease patients in Federal Medical centre, Umuahia, Nigeria. Int. J. Curr. Res. Biol. Med. 2016;1(4):15-21.
14. Obeagu EI. Erythropoeitin in Sickle Cell Anaemia: A Review. International Journal of Research Studies in Medical and Health Sciences. 2020;5(2):22-8.
15. Obeagu EI, Ezimah AC, Obeagu GU. Erythropoietin in the anaemias of pregnancy: a review. Int J Curr Res Chem Pharm Sci. 2016;3(3):10-18.
16. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2016;2(4):29-33.
17. Obeagu EI, Obeagu GU, Nchuma BO, Amazue PO. A Review on erythropoietin receptor (EpoR). Int. J. Adv. Res. Biol. Sci. 2015;2(8):80-84.
18. Obeagu EI. Erythrocyte enumeration and serum erythropoietin in chronic kidney disease patients: A study in Federal Medical Centre, Umuahia, Nigeria. International Journal of Advanced Research in Biological Sciences. 2016;3(7):163-170.
19. Ifeanyi OE. A review on erythropoietin. Int J Adv Res Biol Sci. 2015;2(4):35-47.
20. Obeagu EI. Maximizing longevity: erythropoietin's impact on sickle cell anemia survival rates. Annals of Medicine and Surgery. 2024:10-97.
21. Ifeanyi OE, Uzoma OG. A review on erythropietin in pregnancy. J. Gynecol. Womens Health. 2018;8(3):1-4.
22. Obeagu EI, Okoroiwu IL, Obeagu G. Molecular mechanism and systemic response of erythropoietin: A Review. Int. J. Adv. Res. Biol. Sci. 2015;2(7):58-62.
23. Obeagu EI, Anyiam AF, Obeagu GU. Erythropoietin Therapy in HIV-Infected Individuals: A Critical Review. Elite Journal of HIV. 2024;2(1):51-64.
24. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. Elite Journal of HIV. 2024;2(1):65-78.
25. Obeagu EI. Maximizing longevity: erythropoietin's impact on sickle cell anemia survival rates. Annals of Medicine and Surgery. 2024:10-97.
26. Obeagu EI, Obeagu GU. The Intricate Relationship Between Erythropoietin and HIV-Induced Anemia: Unraveling Pathways for Therapeutic Insights. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):30-40.
27. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. Elite Journal of Nursing and Health Science. 2024;2(1):21-31.

28. Obeagu EI, Eze VU, Alaeboh EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J BioInnovation. 2016; 5:464-471. links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf.
29. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-916. https://www.academia.edu/download/38320140/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma2.EMMA1.pdf.
30. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. Int. J. Adv. Res. Biol. Sci. 2016;3(10): 55-65.DOI; 10.22192/ijarbs.2016.03.10.009
31. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75. links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf
32. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University journal of Medicine and Health Sciences. 2022;2(3):110-119.
33. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30. links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf.
34. Igwe CM, Obeagu IE, Ogbuabor OA. Clinical characteristics of people living with HIV/AIDS on ART in 2014 at tertiary health institutions in Enugu, Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;130. links/645a166f5762c95ac3817d32/Clinical-characteristics-of-people-living-with-HIV-AIDS-on-ART-in-2014-at-tertiary-health-institutions-in-Enugu.pdf.
35. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144. https://www.academia.edu/download/38320159/Obeagu_Emmanuel_Ifeanyi3__et_al.IJCRAR.pdf.

36. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4. links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf
37. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005
38. Obeagu EI, Okoroiwu IL, Obeagu GU. Relationship between Thrombopoietin and Interleukin 3: A Review. Int J Curr Res Chem Pharm. Sci. 2022;9(1):7-13.
39. Obeagu EI, Obeagu GU, Amilo GI. Haematological changes in patients of chronic kidney disease in Umuahia, Abia State, Nigeria. Curr Trends Biomed Eng Biosci. 2018; 11:34-7.
40. Obeagu EI, Okoroiwu IL, Azuonwu O. An update on hypoxic regulation of iron homeostasis and bone marrow environment. Int. J. Curr. Res. Med. Sci. 2018;4(10):42-8.
41. Obeagu EI. Blood Transfusion: A Powerful Process of Saving Anaemic Patients. EC Emergency Medicine and Critical Care. 2020;4(7):33-40.
42. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
43. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. APPLIED SCIENCES (NIJBAS). 2023;3(3).
44. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.
45. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139. links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf.
46. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. Madonna University journal of Medicine and Health Sciences. 2022;2(3):128-134. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86.
47. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International. 2022:29-34.
48. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT:

assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical Research International. 2020;32(24):9-18.

49. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137. links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf.
50. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. Int. J. Adv. Res. Biol. Sci. 2023;10(9):135-142.DOI: 10.22192/ijarbs.2023.10.09.015 links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf
51. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. Int. J. Adv. Res. Biol. Sci. 2023;10(9):128-134.DOI: 10.22192/ijarbs.2023.10.09.014 links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf.
52. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfected with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2017;3(5):100-104.DOI: 10.22192/ijcrms.2017.03.05.014 https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf
53. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. South Asian Journal of Research in Microbiology. 2022;13(2):26-31.
54. Viola N, Kimono E, Nuruh N, Obeagu EI. Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. Asian Journal of Dental and Health Sciences. 2023;3(2):7-14. http://ajdhs.com/index.php/journal/article/view/39.
55. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. J Clin Commun Med. 2020;2(3):180-183.DOI: **DOI:** 10.32474/JCCM.2020.02.000137 links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ElISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf.
56. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy

Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. Journal of Pharmaceutical Research International. 2021;33(47A):78-84.

57. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth. 2023 Jul 29;6(1):203-211. http://research.sdpublishers.net/id/eprint/2819/.
58. Igwe MC, Obeagu EI, Ogbuabor AO, Eze GC, Ikpenwa JN, Eze-Steven PE. Socio-Demographic Variables of People Living with HIV/AIDS Initiated on ART in 2014 at Tertiary Health Institution in Enugu State. Asian Journal of Research in Infectious Diseases. 2022;10(4):1-7.
59. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. Journal of Pharmaceutical Research International. 2021;33(57A):360-368.
60. Igwe MC, Obeagu EI, Ogbuabor AO. ANALYSIS OF THE FACTORS AND PREDICTORS OF ADHERENCE TO HEALTHCARE OF PEOPLE LIVING WITH HIV/AIDS IN TERTIARY HEALTH INSTITUTIONS IN ENUGU STATE. Madonna University journal of Medicine and Health Sciences. 2022;2(3):42-57. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/75.
61. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University journal of Medicine and Health Sciences. 2022;2(3):6-15. https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69
62. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. European Journal of Pharmaceutical and Medical Research, 2023; 10(8): 564-568
63. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETRQVIRAL THERAPY. World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4(3): 153-160**.** links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETRQVIRAL-THERAPY.pdf.
64. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. Int. J. Curr. Res. Biosci. Plant Biol. 2015;2(4):45-49.
65. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. Int. J. Curr. Res. Chem. Pharm. Sci. 2019;6(12):45-8.DOI: 10.22192/ijcrcps.2019.06.12.004

links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf.

66. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. Int. J. Curr. Res. Med. Sci. 2023;9(2):6-13.DOI: 10.22192/ijcrms.2023.09.02.002 links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf.
67. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2016;2(4):29-33. links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf.
68. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. Int. J. Curr. Microbiol. App. Sci. 2015;4(4):906-910. https://www.academia.edu/download/38320134/Obeagu_Emmanuel_Ifeanyi_and_Obeagu__Getrude_Uzoma.EMMA2.pdf.
69. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. Int. J. Curr. Res. Biol. Med. 2016;1(2):1-5.
70. Alum EU, Ugwu OP, Obeagu EI, Okon MB. Curtailing HIV/AIDS Spread: Impact of Religious Leaders. Newport International Journal of Research in Medical Sciences (NIJRMS). 2023;3(2):28-31.
71. Obeagu EI, Obeagu GU, Paul-Chima UO. Stigma Associated With HIV. AIDS: A Review. Newport International Journal of Public Health and Pharmacy (NIJPP). 2023;3(2):64-67.
72. Alum EU, Obeagu EI, Ugwu OP, Aja PM, Okon MB. HIV Infection and Cardiovascular diseases: The obnoxious Duos. Newport International Journal of Research in Medical Sciences (NIJRMS). 2023;3(2):95-99.
73. Ibebuike JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research,* 2018; 1 (2):08-14. https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf.
74. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parametrs in HIV patients before receiving treatment in Aba, Abia State, Nigeria. Res J Pharma Biol Chem Sci. 2014; 5:825-830.
75. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. International Journal of Life Science, Biotechnology and Pharama Research. 2014; 391:186-189.

76. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences. 2023; 3 (1): 7-12.
77. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. International Journal of Innovative and Applied Research. 2022;10(5):1-11.
78. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutiase, vitamins C and E in HIV infected children in Umuahia, Abia state. International Journal of Advanced Research in Biological Sciences. 2015;2(11):268-271.
79. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. Newport International Journal of Scientific and Experimental Sciences (NIJSES). 2023;3(2):56-59.
80. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. Int. J. Curr. Res. Med. Sci. 2018;4(2):104-108.
81. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. Int. J. Adv. Res. Biol. Sci. 2018;5(6):60-66.
82. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. Arch Blood Transfus Disord. 2018;1(2).
83. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75.
84. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
85. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. Medicine (Baltimore). 2023;102(49): e36599. doi: 10.1097/MD.0000000000036599. PMID: 38065920; PMCID: PMC10713174.
86. Anyiam AF, Arinze-Anyiam OC, Irondi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. Medicine (Baltimore). 2023;102(47): e36342. doi: 10.1097/MD.0000000000036342. PMID: 38013335; PMCID: PMC10681551.
87. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. Medicine (Baltimore). 2023;102(47): e35910. doi: 10.1097/MD.0000000000035910. PMID: 38013350; PMCID: PMC10681510.

88. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. Medicine (Baltimore). 2023;102(46): e36166. doi: 10.1097/MD.0000000000036166. PMID: 37986340; PMCID: PMC10659731.
89. Alum EU, Obeagu EI, Ugwu OPC, Samson AO, Adepoju AO, Amusa MO. Inclusion of nutritional counseling and mental health services in HIV/AIDS management: A paradigm shift. Medicine (Baltimore). 2023;102(41): e35673. doi: 10.1097/MD.0000000000035673. PMID: 37832059; PMCID: PMC10578718.
90. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Sci Rep. 2023;6(8): e1450. doi: 10.1002/hsr2.1450. PMID: 37520460; PMCID: PMC10375546.
91. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. APPLIED SCIENCES (NIJBAS). 2023;3(3).
92. Hilderman M, Bruchfeld A. The cholinergic anti-inflammatory pathway in chronic kidney disease—review and vagus nerve stimulation clinical pilot study. Nephrology Dialysis Transplantation. 2020;35(11):1840-1852.
93. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(11):14-25.
94. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. Int. J. Adv. Multidiscip. Res. 2023;10(10):56-62.
95. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. Newport International Journal of Scientific and Experimental Sciences (NIJSES). 2023;3(2):56-9.
96. Alum EU, Ugwu OP, Obeagu EI, Aja PM, Okon MB, Uti DE. Reducing HIV Infection Rate in Women: A Catalyst to reducing HIV Infection pervasiveness in Africa. International Journal of Innovative and Applied Research. 2023;11(10):01-6.
97. Obeagu EI, Obeagu GU. Unmasking the Truth: Addressing Stigma in the Fight Against HIV. Elite Journal of Public Health. 2024;2(1):8-22.
98. Obeagu EI, Obeagu GU, Ukibe NR, Oyebadejo SA. Anemia, iron, and HIV: decoding the interconnected pathways: A review. Medicine. 2024 Jan 12;103(2):e36937.
99. Obeagu EI, Obeagu GU. Utilization of immunological ratios in HIV: Implications for monitoring and therapeutic strategies. Medicine. 2024 Mar 1;103(9):e37354.
100. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. Elite Journal of Laboratory Medicine. 2024;2(1):46-58.
101. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. Elite Journal of Medicine. 2024;2(1):35-46.

102. Obeagu EI, Obeagu GU, Odo EO, Igwe MC, Ugwu OP, Alum EU, Racheal P. Combatting Stigma: Essential Steps in Halting HIV Spread. IAA Journal of Applied Sciences. 2024;11(1):22-9.
103. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. Elite Journal of HIV. 2024;2(1):65-78.
104. Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. Elite Journal of Medicine. 2024;2(1):10-22.
105. Obeagu EI, Obeagu GU. Eosinophil Dynamics in Pregnancy among Women Living with HIV: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024;10(1):11-24.
106. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024;10(1):25-36.
107. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Neutrophil Dynamics: Unveiling Their Role in HIV Progression within Malaria Patients. Journal home page: http://www. journalijiar. com.;12(01).
108. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
109. Obeagu EI, Obeagu GU. Platelet-Driven Modulation of HIV: Unraveling Interactions and Implications. Journal home page: http://www. journalijiar. com.;12(01).
110. Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. Elite Journal of Laboratory Medicine. 2024;2(1):33-45.
111. Obeagu EI, Ubosi NI, Obeagu GU, Obeagu AA. Nutritional Strategies for Enhancing Immune Resilience in HIV: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):41-51.
112. Obeagu EI, Anyiam AF, Obeagu GU. Erythropoietin Therapy in HIV-Infected Individuals: A Critical Review. Elite Journal of HIV. 2024;2(1):51-64.
113. Obeagu EI , Obeagu GU. Synergistic Effects of Blood Transfusion and HIV in Children Under 5 Years with Severe Malaria: A Review. Elite Journal of HIV. 2024;2(1):31-50.
114. Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. Elite Journal of HIV. 2024;2(1):16-30.
115. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. Elite Journal of Haematology. 2024;2(1):26-41.
116. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. Sciences. 2024;4(1):32-7.

117. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. Sciences. 2024;4(1):38-44.
118. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. Elite Journal of Health Science. 2024;2(1):33-42.
119. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. Elite Journal of Public Health. 2024;2(1):52-61.
120. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. Elite Journal of Nursing and Health Science. 2024;2(1):21-31.
121. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
122. Obeagu EI, Obeagu GU. The Intricate Relationship Between Erythropoietin and HIV-Induced Anemia: Unraveling Pathways for Therapeutic Insights. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):30-40.
123. Pan Z, Zhang X, Xie W, Cui J, Wang Y, Zhang B, Du L, Zhai W, Sun H, Li Y, Li D. Revisited and innovative perspectives of oral ulcer: from biological specificity to local treatment. Frontiers in Bioengineering and Biotechnology. 2024; 12:1335377.
124. Ronaldson PT, Williams EI, Betterton RD, Stanton JA, Nilles KL, Davis TP. CNS Drug Delivery in Stroke: Improving Therapeutic Translation from the Bench to the Bedside. Stroke. 2024;55(1):190-202.